Literature DB >> 25822899

Growth pattern of colorectal liver metastasis as a marker of recurrence risk.

R L Eefsen1, P B Vermeulen, I J Christensen, O D Laerum, M B Mogensen, H C Rolff, G G Van den Eynden, G Høyer-Hansen, K Osterlind, B Vainer, M Illemann.   

Abstract

Despite improved therapy of advanced colorectal cancer, the median overall survival (OS) is still low. A surgical removal has significantly improved survival, if lesions are entirely removed. The purpose of this retrospective explorative study was to evaluate the prognostic value of histological growth patterns (GP) in chemonaive and patients receiving neo-adjuvant therapy. Two-hundred-fifty-four patients who underwent liver resection of colorectal liver metastases between 2007 and 2011 were included in the study. Clinicopathological data and information on neo-adjuvant treatment were retrieved from patient and pathology records. Histological GP were evaluated and related to recurrence free and OS. Kaplan-Meier curves, log-rank test and Cox regression analysis were used. The 5-year OS was 41.8% (95% CI 33.8-49.8%). Growth pattern evaluation of the largest liver metastasis was possible in 224 cases, with the following distribution: desmoplastic 63 patients (28.1%); pushing 77 patients (34.4%); replacement 28 patients (12.5%); mixed 56 patients (25.0%). The Kaplan-Meier analyses demonstrated that patients resected for liver metastases with desmoplastic growth pattern had a longer recurrence free survival (RFS) than patients resected for non-desmoplastic liver metastases (p=0.05). When patients were stratified according to neo-adjuvant treatment in the multivariate Cox regression model, hazard ratios for RFS compared to desmoplastic were: pushing (HR=1.37, 95% CI 0.93-2.02, p=0.116), replacement (HR=2.16, 95% CI 1.29-3.62, p=0.003) and mixed (HR=1.70, 95% CI 1.12-2.59, p=0.013). This was true for chemonaive patients as well as for patients who received neo-adjuvant treatment.

Entities:  

Mesh:

Year:  2015        PMID: 25822899     DOI: 10.1007/s10585-015-9715-4

Source DB:  PubMed          Journal:  Clin Exp Metastasis        ISSN: 0262-0898            Impact factor:   5.150


  51 in total

1.  Liver anatomy: portal (and suprahepatic) or biliary segmentation.

Authors:  C Couinaud
Journal:  Dig Surg       Date:  1999       Impact factor: 2.588

2.  Reporting Recommendations for Tumor Marker Prognostic Studies (REMARK): explanation and elaboration.

Authors:  Douglas G Altman; Lisa M McShane; Willi Sauerbrei; Sheila E Taube
Journal:  PLoS Med       Date:  2012-05-29       Impact factor: 11.069

3.  Perioperative FOLFOX4 chemotherapy and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC 40983): long-term results of a randomised, controlled, phase 3 trial.

Authors:  Bernard Nordlinger; Halfdan Sorbye; Bengt Glimelius; Graeme J Poston; Peter M Schlag; Philippe Rougier; Wolf O Bechstein; John N Primrose; Euan T Walpole; Meg Finch-Jones; Daniel Jaeck; Darius Mirza; Rowan W Parks; Murielle Mauer; Erik Tanis; Eric Van Cutsem; Werner Scheithauer; Thomas Gruenberger
Journal:  Lancet Oncol       Date:  2013-10-11       Impact factor: 41.316

4.  Tumor growth pattern as predictor of colorectal liver metastasis recurrence.

Authors:  Rafael S Pinheiro; Paulo Herman; Renato M Lupinacci; Quirino Lai; Evandro S Mello; Fabricio F Coelho; Marcos V Perini; Vincenzo Pugliese; Wellington Andraus; Ivan Cecconello; Luiz Carneiro D'Albuquerque
Journal:  Am J Surg       Date:  2013-10-07       Impact factor: 2.565

5.  Clinical determinants of survival in patients with 5-fluorouracil-based treatment for metastatic colorectal cancer: results of a multivariate analysis of 3825 patients.

Authors:  C H Köhne; D Cunningham; F Di Costanzo; B Glimelius; G Blijham; E Aranda; W Scheithauer; P Rougier; M Palmer; J Wils; B Baron; F Pignatti; P Schöffski; S Micheel; H Hecker
Journal:  Ann Oncol       Date:  2002-02       Impact factor: 32.976

6.  Clinicopathological features and prognosis in resectable synchronous and metachronous colorectal liver metastasis.

Authors:  Ming-Shian Tsai; Yen-Hao Su; Ming-Chih Ho; Jin-Tung Liang; Tzu-Ping Chen; Hong-Shiee Lai; Po-Huang Lee
Journal:  Ann Surg Oncol       Date:  2006-11-14       Impact factor: 5.344

7.  Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study.

Authors:  Leonard B Saltz; Stephen Clarke; Eduardo Díaz-Rubio; Werner Scheithauer; Arie Figer; Ralph Wong; Sheryl Koski; Mikhail Lichinitser; Tsai-Shen Yang; Fernando Rivera; Felix Couture; Florin Sirzén; Jim Cassidy
Journal:  J Clin Oncol       Date:  2008-04-20       Impact factor: 44.544

Review 8.  Recurrence patterns after resection of liver metastases from colorectal cancer.

Authors:  Halfdan Sorbye
Journal:  Recent Results Cancer Res       Date:  2014

9.  Two distinct expression patterns of urokinase, urokinase receptor and plasminogen activator inhibitor-1 in colon cancer liver metastases.

Authors:  Martin Illemann; Nigel Bird; Ali Majeed; Ole D Laerum; Leif R Lund; Keld Danø; Boye Schnack Nielsen
Journal:  Int J Cancer       Date:  2009-04-15       Impact factor: 7.396

10.  Surgery for colorectal liver metastases: the impact of resection margins on recurrence and overall survival.

Authors:  Jon-Helge Angelsen; Arild Horn; Geir Egil Eide; Asgaut Viste
Journal:  World J Surg Oncol       Date:  2014-04-27       Impact factor: 2.754

View more
  34 in total

1.  miR-193b directly targets STMN1 and inhibits the malignant phenotype in colorectal cancer.

Authors:  Feng Guo; Yang Luo; Yi-Fei Mu; Shao-Lan Qin; Yang Qi; Yi-Er Qiu; Ming Zhong
Journal:  Am J Cancer Res       Date:  2016-11-01       Impact factor: 6.166

2.  Histopathological growth patterns and positive margins after resection of colorectal liver metastases.

Authors:  Pieter M H Nierop; Diederik J Höppener; Eric P van der Stok; Boris Galjart; Florian E Buisman; Vinod P Balachandran; William R Jarnagin; T Peter Kingham; Peter J Allen; Jinru Shia; Peter B Vermeulen; Bas Groot Koerkamp; Dirk J Grünhagen; Cornelis Verhoef; Michael I D'Angelica
Journal:  HPB (Oxford)       Date:  2019-11-15       Impact factor: 3.647

3.  Differentiation of histopathological growth patterns of colorectal liver metastases by MRI features.

Authors:  Wen-Hui Li; Shuai Wang; Yi Liu; Xin-Fang Wang; Yong-Feng Wang; Rui-Mei Chai
Journal:  Quant Imaging Med Surg       Date:  2022-01

4.  The Histopathological Growth Pattern of Colorectal Liver Metastases Impacts Local Recurrence Risk and the Adequate Width of the Surgical Margin.

Authors:  L Viganò; B Branciforte; V Laurenti; G Costa; F Procopio; M Cimino; D Del Fabbro; L Di Tommaso; G Torzilli
Journal:  Ann Surg Oncol       Date:  2022-06-10       Impact factor: 4.339

Review 5.  Histopathological growth patterns of liver metastasis: updated consensus guidelines for pattern scoring, perspectives and recent mechanistic insights.

Authors:  Emily Latacz; Diederik Höppener; Ali Bohlok; Vincent Donckier; Peter M Siegel; Raymond Barnhill; Marco Gerling; Cornelis Verhoef; Peter B Vermeulen; Sophia Leduc; Sébastien Tabariès; Carlos Fernández Moro; Claire Lugassy; Hanna Nyström; Béla Bozóky; Giuseppe Floris; Natalie Geyer; Pnina Brodt; Laura Llado; Laura Van Mileghem; Maxim De Schepper; Ali W Majeed; Anthoula Lazaris; Piet Dirix; Qianni Zhang; Stéphanie K Petrillo; Sophie Vankerckhove; Ines Joye; Yannick Meyer; Alexander Gregorieff; Nuria Ruiz Roig; Fernando Vidal-Vanaclocha; Larsimont Denis; Rui Caetano Oliveira; Peter Metrakos; Dirk J Grünhagen; Iris D Nagtegaal; David G Mollevi; William R Jarnagin; Michael I D'Angelica; Andrew R Reynolds; Michail Doukas; Christine Desmedt; Luc Dirix
Journal:  Br J Cancer       Date:  2022-06-01       Impact factor: 9.075

Review 6.  Emerging roles for lncRNA-NEAT1 in colorectal cancer.

Authors:  Shirin Azizidoost; Farhoodeh Ghaedrahmati; Omid Anbiyaee; Riyadh Ahmad Ali; Maryam Cheraghzadeh; Maryam Farzaneh
Journal:  Cancer Cell Int       Date:  2022-06-08       Impact factor: 6.429

7.  mRNA expression profiles of colorectal liver metastases as a novel biomarker for early recurrence after partial hepatectomy.

Authors:  E P van der Stok; M Smid; A M Sieuwerts; P B Vermeulen; S Sleijfer; N Ayez; D J Grünhagen; J W M Martens; C Verhoef
Journal:  Mol Oncol       Date:  2016-09-20       Impact factor: 6.603

8.  Inflammation and uPAR-Expression in Colorectal Liver Metastases in Relation to Growth Pattern and Neo-adjuvant Therapy.

Authors:  R L Eefsen; L Engelholm; W Alpizar-Alpizar; G G E Van den Eynden; P B Vermeulen; I J Christensen; O D Laerum; H C Rolff; G Høyer-Hansen; B Vainer; K Osterlind; M Illemann
Journal:  Cancer Microenviron       Date:  2015-08-14

Review 9.  Vessel co-option in cancer.

Authors:  Elizabeth A Kuczynski; Peter B Vermeulen; Francesco Pezzella; Robert S Kerbel; Andrew R Reynolds
Journal:  Nat Rev Clin Oncol       Date:  2019-08       Impact factor: 66.675

10.  MiR-27b directly targets Rab3D to inhibit the malignant phenotype in colorectal cancer.

Authors:  Yang Luo; Shi-Yong Yu; Jian-Jun Chen; Jun Qin; Yi-Er Qiu; Ming Zhong; Min Chen
Journal:  Oncotarget       Date:  2017-12-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.